RXST RxSight Inc.

Medical Device Company
13.35
+0.88  (+7%)
Previous Close 12.47
Open 12.78
52 Week Low 8.8
52 Week High 19.6699
Market Cap $367,193,659
Shares 27,505,143
Float 18,304,496
Enterprise Value $241,844,721
Volume 48,294
Av. Daily Volume 112,810
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/06/2022
Needham Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/06/2022
Needham Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/08/2022

Latest News

  1. ALISO VIEJO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended March 31, 2022.

    Key Quarterly Highlights:

    • Delivered first quarter 2022 revenue of $8.9 million, an increase of 157% compared to the first quarter of 2021, reflecting:
      • The sale of 40 Light Delivery Devices (LDD™s), representing a 208% unit increase from the first quarter of 2021, expanding the installed base to 246 LDDs at the end of the quarter, a 134% increase compared to the 105 LDD installed base at the end of the first quarter of 2021.
      • The sale of 4,166 Light Adjustable Lenses (LAL®s…
    View Full Article
  2. ALISO VIEJO, Calif. , April 19, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that its Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various surgeon presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Washington D.C. on April 22-26, 2022.   

    The following are posters and papers accepted for presentation:

    Friday, April 22:

    Evaluation of Clinical Outcomes after Implantation of an IOL That Can Be Optimized with UV Light Compared to an Extended

    View Full Article
View All RxSight Inc. News